Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial

OBJECTIVE: Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double‐blind, placebo‐controlled trial was to evaluate the efficacy and safety of evobrutinib in patients with active autoantibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallace, Daniel J., Dörner, Thomas, Pisetsky, David S., Sanchez‐Guerrero, Jorge, Patel, Anand C., Parsons‐Rich, Dana, Le Bolay, Claire, Drouin, Elise E., Kao, Amy H., Guehring, Hans, Dall'Era, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837396/
https://www.ncbi.nlm.nih.gov/pubmed/36530019
http://dx.doi.org/10.1002/acr2.11511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837396/
https://www.ncbi.nlm.nih.gov/pubmed/36530019
http://dx.doi.org/10.1002/acr2.11511

Ejemplares similares